Resistance in Hepatitis C
Source: Clinical Implications of HCV Resistance: Laying the Foundation for Optimal Treatment Today and in the Future

Module

Join Stephane Chevaliez, PharmD, PhD; Paul J. Pockros, MD; and Stefan Zeuzem, MD, as they review and discuss key principles of HCV resistance with currently approved direct-acting antiviral agents, the latest resistance data on agents in development, and important considerations for potential future anti-HCV regimens. These expert faculty members also provide practical strategies for clinical challenges with the newly approved direct-acting agents through a case-based analysis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply strategies to reduce the development/expansion of resistance to direct-acting antiviral agents when managing patients receiving treatment with approved direct-acting antiviral agents in combination with peginterferon/ribavirin
  • Integrate key principles regarding antiviral resistance when evaluating data on the direct-acting antiviral agents currently in development
  • Evaluate potential future strategies for HCV treatment based on resistance considerations, including the barrier to resistance and patterns of cross-resistance among classes of direct-acting antiviral agents

Topics covered include:

  • Introduction to Drug Resistance in Hepatitis C Virus
  • Key Resistance Principles for Currently Approved Direct-Acting Antiviral Agents
  • Considerations for Retreatment of Previous Peginterferon/Ribavirin Null Responders and Potential Consequences of Protease Inhibitor Resistance
  • Genotype and Resistance Testing
  • Case 1: Previous Null Responder
  • Case 2: Stopping Rules
  • Case 3: Boceprevir Resistance–Associated Variant
  • Future Regimens
  • Future Protease Inhibitors
  • Nucleos(t)ide Polymerase Inhibitors
  • Nonnucleos(t)ide Polymerase Inhibitors
  • NS5A Inhibitors
  • Cyclophilin Inhibitors
  • Summary: Important Considerations to Avoid Resistance-Associated Variants
  • Appendix: Principles of HCV Resistance
 

Program Directors

  • Stefan Zeuzem
    MD

Faculty

  • Stéphane Chevaliez
    PharmD, PhD
    Paul J. Pockros
    MD

Credit Information

  • Release Date:
    October 25, 2011
  • Expiration Date:
    October 24, 2012
  • Physicians:
    maximum of 1.25 AMA PRA Category 1 Credits
  • My Take on the Guidance From AASLD/IDSA for Managing Treatment-Experienced Patients With Genotype 1 HCV Infection and Cirrhosis

    Nezam H. Afdhal MD, FRCPI - 11/4/2014    2 comments / Last Comment: 11/15/2014
    New regimens are becoming available for genotype 1 HCV infection that offer more data and apparently better efficacy than previously recommended regimens in patients with cirrhosis who have experienced previous treatment failure.
  • My Take on the Guidance From AASLD/IDSA for Treating Patients With Genotype 2 HCV Infection

    Norah Terrault MD, MPH - 11/4/2014    
    The AASLD/IDSA HCV guidance is straight forward regarding treatment-naive patients with genotype 2 HCV infection, but there are a few considerations to keep in mind.
  • How Does the AASLD/IDSA HCV Guidance Weigh in on Management of HIV Coinfection?

    Douglas T. Dieterich MD - 10/9/2014    1 comment / Last Comment: 10/24/2014
    There is great interest in offering coinfected patients the same opportunity for cure as monoinfected patients. The AASLD/IDSA guidance has developed recommendations aimed at maximizing cure in different populations of coinfected individuals.
  • My Take on the Guidance From AASLD/IDSA for Treating PI-Experienced Patients With Genotype 1 HCV Infection

    Norah Terrault MD, MPH - 11/4/2014    1 comment / Last Comment: 11/16/2014
    In this rapidly evolving treatment environment, the best available regimen may not yet have been incorporated into the expert guidance.
  • All-Oral Therapy for HCV: Rewriting the Course of the Disease

    Nancy Reau MD - 11/3/2014    2 comments / Last Comment: 11/19/2014
    All-oral HCV therapies are erasing the importance of traditional obstacles to cure